An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

2010375 citationsJournal Article

Authors

Michael E. Weinblatt · Harvard University

Arthur Kavanaugh · University of California, San Diego

Mark C. Genovese

Theresa K. Musser · Rigel (United States)

Elliott B. Grossbard · Rigel (United States)

Daniel B. Magilavy · Rigel (United States)

Abstract

In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia. Additional studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis. (Funded by Rigel; ClinicalTrials.gov number, NCT00665925.)

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research Mast cells and histamine Rheumatoid Arthritis Research and Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 14, pp. 1303-1312

DOI: 10.1056/nejmoa1000500

Field-Weighted Citation Impact: 40.93